Abivax Stock Soars 400% on Positive Phase 3 Results

Abivax's stock surged by 400% in pre-market trading on July 23, 2025, marking a significant milestone for the company.

Abivax recently announced positive Phase 3 results from both ABTECT 8-week induction trials, which investigated Obefazimod, its first-in-class oral miR-124 enhancer. The ABTECT program is noted as one of the largest Phase 3 ulcerative colitis trials ever conducted. The drug candidate demonstrated a placebo-adjusted remission rate of 19.3% in the first study and 13.4% in the second study, meeting its main goal in both large Phase 3 studies. This achievement shows a clear benefit over placebo in achieving clinical remission after eight weeks of treatment.

The positive Phase 3 results have significantly boosted investor confidence in Abivax, contributing to the stock's strong momentum. The company's focus on innovative treatments for ulcerative colitis has positioned it as a leader in the field, with the potential to revolutionize patient care.